Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

General Research Article

Impaired Fasting Glucose (IFG) Prevalence Among Hypolipidemic Treatment- naïve Patients with Hypertension

Author(s): John Papadakis, Petros Ioannou, George Vrentzos, Vasiliki Theodorakopoulou, Konstantinos Papanikolaou and Theodosios Filippatos*

Volume 18, Issue 2, 2022

Published on: 07 July, 2022

Page: [153 - 157] Pages: 5

DOI: 10.2174/1573402118666220321121421

Price: $65

Abstract

Background: Impaired fasting glucose (IFG) predisposes to the future development of type 2 diabetes mellitus (T2DM) and may also be associated with increased cardiovascular disease (CVD) risk. Hypertension is an established CVD risk factor.

Objective: This study aimed to assess the prevalence of IFG and the associated anthropometric and metabolic disturbances in patients with hypertension.

Methods: Consecutive hypertensive patients not on any hypolipidemic treatment and without a diagnosis of T2DM were included. IFG was defined as serum glucose ≥100 mg/dl according to the American Diabetes Association criteria.

Results: The total sample consisted of 1381 participants; between them, 78 patients were diagnosed to have T2DM and they were excluded from the analyses, leaving a final sample of 1303 hypertensive patients [41.0% men; median age 58 (range: 15-90) years] not on any hypolipidemic treatment and without a diagnosis of T2DM. IFG was identified in 469 patients (36%). IFG was more prevalent in males than in females (42.4% vs. 31.8%, p<0.001). Patients with IFG had greater body mass index (BMI), waist-to-hip ratio, systolic blood pressure, pulse pressure, triglycerides, alanine aminotransferase, gamma-glutamyl transferase, and uric acid serum levels compared with patients with normal serum glucose levels.

Conclusion: This study reveals that in a sample of patients with hypertension, one out of three has IFG. This is more prevalent among men. IFG is associated with the presence of a more aggravated anthropometric and biochemical profile, possibly associated with an increased CVD risk.

Keywords: Hypertension, blood pressure, cardiovascular risk, prediabetes, impaired fasting glucose, diabetes.

[1]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[2]
American Diabetes Association. Standards of medical care in diabetes-2021 abridged for primary care providers. Clin Diabetes 2021; 39(1): 14-43.
[http://dx.doi.org/10.2337/cd21-as01] [PMID: 33551551]
[3]
Filippatos TD, Panagiotakos DB, Georgousopoulou EN, et al. Mediterranean Diet and 10-year (2002-2012) Incidence of Diabetes and Cardiovascular Disease in Participants with Prediabetes: The ATTICA study. Rev Diabet Stud 2016; 13(4): 226-35.
[http://dx.doi.org/10.1900/RDS.2016.13.226] [PMID: 28278309]
[4]
Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ 2016; 355: i5953.
[http://dx.doi.org/10.1136/bmj.i5953] [PMID: 27881363]
[5]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[6]
Eades CE, France EF, Evans JMM. Prevalence of impaired glucose regulation in Europe: A meta-analysis. Eur J Public Health 2016; 26(4): 699-706.
[http://dx.doi.org/10.1093/eurpub/ckw085] [PMID: 27423001]
[7]
Tramunt B, Smati S, Grandgeorge N, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia 2020; 63(3): 453-61.
[http://dx.doi.org/10.1007/s00125-019-05040-3] [PMID: 31754750]
[8]
Sasaki N, Ozono R, Higashi Y, Maeda R, Kihara Y. Association of insulin resistance, plasma glucose level, and serum insulin level with hypertension in a population with different stages of impaired glucose metabolism. J Am Heart Assoc 2020; 9(7): e015546.
[http://dx.doi.org/10.1161/JAHA.119.015546] [PMID: 32200720]
[9]
Bjørnholt JV, Erikssen G, Kjeldsen SE, Bodegård J, Thaulow E, Erikssen J. Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure. J Hypertens 2003; 21(7): 1383-9.
[http://dx.doi.org/10.1097/00004872-200307000-00029] [PMID: 12817188]
[10]
Lee CJ, Lim N-K, Kim H-C, et al. Impaired fasting glucose and impaired glucose tolerance do not predict hypertension: A community cohort study. Am J Hypertens 2015; 28(4): 493-500.
[http://dx.doi.org/10.1093/ajh/hpu186] [PMID: 25267735]
[11]
Benetos A, Okuda K, Lajemi M, et al. Telomere length as an indicator of biological aging: The gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001; 37(2 Pt 2): 381-5.
[http://dx.doi.org/10.1161/01.HYP.37.2.381] [PMID: 11230304]
[12]
Shimokata H, Muller DC, Fleg JL, Sorkin J, Ziemba AW, Andres R. Age as independent determinant of glucose tolerance. Diabetes 1991; 40(1): 44-51.
[http://dx.doi.org/10.2337/diab.40.1.44] [PMID: 2015973]
[13]
Chia CW, Egan JM, Ferrucci L. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk. Circ Res 2018; 123: 886-904.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.312806]
[14]
Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol 2019; 15(9): 507-24.
[http://dx.doi.org/10.1038/s41574-019-0230-6] [PMID: 31296970]
[15]
Kotsis V, Tsioufis K, Antza C, et al. Obesity and cardiovascular risk: A call for action from the European society of hypertension working group of obesity, diabetes and the high-risk patient and european association for the study of obesity: Part B: Obesity-induced cardiovascular disease, early prevention strategies and future research directions. J Hypertens 2018; 36(7): 1441-55.
[http://dx.doi.org/10.1097/HJH.0000000000001731] [PMID: 29652731]
[16]
Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A2 in subjects with prediabetes. Lipids 2013; 48(6): 547-55.
[http://dx.doi.org/10.1007/s11745-013-3787-1] [PMID: 23546765]
[17]
Della Corte C, Mosca A, Majo F, et al. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: More than ectopic fat. Clin Endocrinol (Oxf) 2015; 83(5): 656-62.
[http://dx.doi.org/10.1111/cen.12862] [PMID: 26201937]
[18]
Filippatos TD, Alexakis K, Mavrikaki V, Mikhailidis DP. Nonalcoholic fatty pancreas disease: Role in metabolic syndrome, “prediabetes,” diabetes and atherosclerosis. Dig Dis Sci 2021; 1-6.
[http://dx.doi.org/10.1007/s10620-021-06824-7] [PMID: 33469809]
[19]
Anothaisintawee T, Lertrattananon D, Thamakaison S, Reutrakul S, Ongphiphadhanakul B, Thakkinstian A. Direct and indirect effects of serum uric acid on blood sugar levels in patients with prediabetes: A mediation analysis. J Diabetes Res 2017; 2017: 6830671.
[http://dx.doi.org/10.1155/2017/6830671] [PMID: 29214183]
[20]
van der Schaft N, Brahimaj A, Wen K-X, Franco OH, Dehghan A. The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study. PLoS One 2017; 12(6): e0179482.
[http://dx.doi.org/10.1371/journal.pone.0179482] [PMID: 28632742]
[21]
Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta 2018; 484: 150-63.
[http://dx.doi.org/10.1016/j.cca.2018.05.046] [PMID: 29803897]
[22]
Rahimi-Sakak F, Maroofi M, Rahmani J, Bellissimo N, Hekmatdoost A. Serum uric acid and risk of cardiovascular mortality: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc Disord 2019; 19(1): 218.
[http://dx.doi.org/10.1186/s12872-019-1215-z] [PMID: 31615412]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy